X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Merz Therapeutics will purchase substantially all of the assets of Acorda, including the rights to Inbrija (levodopa inhalation powder), Ampyra (dalfampridine), and Fampyra (dalfampridine). INBRIJA is used when needed for OFF episodes in adults with Parkinson's disease.
Lead Product(s): Etilevodopa
Therapeutic Area: Neurology Product Name: Inbrija
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Acorda Therapeutics
Deal Size: $185.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition April 02, 2024
Details:
Study Design of LONG RUN: A LONGitudinal evaluation and real-world evidence of uniquely purified incobotulinumtoxinA in treatment naïve participants, demonstrates safety and prolonged duration of effect in a dose-ranging study for glabellar lines
Lead Product(s): Incobotulinumtoxin A
Therapeutic Area: Dermatology Product Name: Xeomin
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 31, 2022
Details:
The approval by European authorities for the use of XEOMIN® for pediatric patients suffering from chronic sialorrhea, was achieved due to the convincing results of the SIPEXI study (Sialorrhea Pediatric Xeomin Investigation).
Lead Product(s): IncobotulinumtoxinA
Therapeutic Area: Neurology Product Name: Xeomin
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 31, 2021
Details:
Xeomin ® is effective in the treatment of peripheral cholinergic nerve endings by decreasing the contraction of voluntary muscles, and relieves muscle tone by inhibiting the release of a neurotransmitter, acetylcholine.
Lead Product(s): IncobotulinumtoxinA
Therapeutic Area: Neurology Product Name: Xeomin
Highest Development Status: ApprovedProduct Type: Large molecule
Recipient: Teijin Pharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 23, 2021
Details:
The strategic cooperation between the two parties marks the obtainment of Winhealth Pharma for the exclusive commercial rights of Hepa-Merz® (L-ornithine L-aspartate, an important product under Merz' product portfolio) in China.
Lead Product(s): L-Ornithine L-aspartate
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Hepa-Merz
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Winhealth Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 08, 2021
Details:
XEOMIN was licensed by Health Canada for adult patients with sialorrhea on the basis of a Phase III, randomized, double-blind, placebo-controlled, multicenter trial in which 184 patients participated.
Lead Product(s): IncobotulinumtoxinA
Therapeutic Area: Neurology Product Name: Xeomin
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 01, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
